Switch to:
Also traded in: Austria, Germany, Israel, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.06
MYL's Cash-to-Debt is ranked lower than
94% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. MYL: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
MYL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 6.63 Max: N/A
Current: 0.06
Equity-to-Asset 0.34
MYL's Equity-to-Asset is ranked lower than
85% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYL: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
MYL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.83 Max: 0.94
Current: 0.34
0.19
0.94
Interest Coverage 1.57
MYL's Interest Coverage is ranked lower than
91% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. MYL: 1.57 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.29 Max: 8.18
Current: 1.57
0.83
8.18
Piotroski F-Score: 4
Altman Z-Score: 1.26
Beneish M-Score: -2.69
WACC vs ROIC
9.82%
4.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 7.09
MYL's Operating Margin % is ranked lower than
54% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. MYL: 7.09 )
Ranked among companies with meaningful Operating Margin % only.
MYL' s Operating Margin % Range Over the Past 10 Years
Min: 5.8  Med: 15.91 Max: 26.53
Current: 7.09
5.8
26.53
Net Margin % 4.59
MYL's Net Margin % is ranked lower than
56% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. MYL: 4.59 )
Ranked among companies with meaningful Net Margin % only.
MYL' s Net Margin % Range Over the Past 10 Years
Min: -3.53  Med: 8.88 Max: 13.48
Current: 4.59
-3.53
13.48
ROE % 4.82
MYL's ROE % is ranked lower than
57% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. MYL: 4.82 )
Ranked among companies with meaningful ROE % only.
MYL' s ROE % Range Over the Past 10 Years
Min: -14.72  Med: 14.08 Max: 29.99
Current: 4.82
-14.72
29.99
ROA % 1.70
MYL's ROA % is ranked lower than
60% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. MYL: 1.70 )
Ranked among companies with meaningful ROA % only.
MYL' s ROA % Range Over the Past 10 Years
Min: -2.47  Med: 4.52 Max: 7.1
Current: 1.7
-2.47
7.1
ROC (Joel Greenblatt) % 16.09
MYL's ROC (Joel Greenblatt) % is ranked higher than
55% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. MYL: 16.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.32  Med: 28.81 Max: 47.2
Current: 16.09
14.32
47.2
3-Year Revenue Growth Rate 6.70
MYL's 3-Year Revenue Growth Rate is ranked higher than
56% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. MYL: 6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.1  Med: 15.2 Max: 54.5
Current: 6.7
-6.1
54.5
3-Year EBITDA Growth Rate 0.30
MYL's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. MYL: 0.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.4  Med: 11.1 Max: 107.9
Current: 0.3
-20.4
107.9
3-Year EPS without NRI Growth Rate -16.50
MYL's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. MYL: -16.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.1  Med: 8.1 Max: 110.4
Current: -16.5
-29.1
110.4
GuruFocus has detected 4 Warning Signs with Mylan NV $MYL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYL's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MYL Guru Trades in Q3 2016

Joel Greenblatt 21,460 sh (New)
David Einhorn 6,400,000 sh (+29.42%)
Paul Tudor Jones 10,900 sh (+16.52%)
Mario Gabelli 16,012 sh (+14.37%)
Vanguard Health Care Fund 29,148,837 sh (+4.23%)
Pioneer Investments 54,839 sh (+1.28%)
Scott Black 41,176 sh (+0.08%)
John Paulson 940,400 sh (unchged)
John Paulson 21,811,661 sh (-0.98%)
Lee Ainslie 1,336,436 sh (-41.76%)
» More
Q4 2016

MYL Guru Trades in Q4 2016

David Tepper 3,275,000 sh (New)
Jim Simons 1,504,000 sh (New)
First Pacific Advisors 3,085,731 sh (New)
Lee Ainslie 3,799,281 sh (+184.28%)
David Einhorn 8,670,307 sh (+35.47%)
Vanguard Health Care Fund 30,084,537 sh (+3.21%)
Mario Gabelli 16,512 sh (+3.12%)
John Paulson 904,200 sh (unchged)
Joel Greenblatt Sold Out
Scott Black 40,841 sh (-0.81%)
Pioneer Investments 54,144 sh (-1.27%)
John Paulson 20,602,500 sh (-5.54%)
Paul Tudor Jones 5,500 sh (-49.54%)
» More
Q1 2017

MYL Guru Trades in Q1 2017

Joel Greenblatt 648,342 sh (New)
Richard Pzena 7,262,316 sh (New)
Steven Cohen 3,602,271 sh (New)
Paul Tudor Jones 99,063 sh (+1701.15%)
First Pacific Advisors 5,349,600 sh (+73.37%)
Jim Simons 2,488,400 sh (+65.45%)
David Einhorn 8,692,307 sh (+0.25%)
John Paulson 200,000 sh (unchged)
Steven Cohen 40,000 sh (unchged)
Scott Black 40,821 sh (-0.05%)
Vanguard Health Care Fund 29,295,842 sh (-2.62%)
Mario Gabelli 14,500 sh (-12.19%)
John Paulson 17,274,387 sh (-16.15%)
Pioneer Investments 35,014 sh (-35.33%)
David Tepper 1,900,000 sh (-41.98%)
Lee Ainslie 1,545,448 sh (-59.32%)
» More
Q2 2017

MYL Guru Trades in Q2 2017

Steven Romick 6,341,690 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:MNK, LSE:HIK, LSE:BMK, LSE:APH, LSE:STX, LSE:SPH, LSE:SUMM, LSE:QP., LSE:DNL, LSE:AMYT, LSE:SIS, LSE:VLG, LSE:EVG » details
Traded in other countries:MYL.Austria, 6MY.Germany, MYL.Israel, MYL1.Switzerland, 0R5P.UK,
Headquarter Location:UK
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.

Mylan is the world's fourth-largest generic pharmaceutical manufacturer with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales comprise approximately 84% of revenue. Remaining sales come from a handful of branded products, primarily the epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

Guru Investment Theses on Mylan NV

John Keeley Comments on Mylan Labs - Apr 26, 2016

Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Keeley Funds Comments on Mylan N.V. - Feb 03, 2016

The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

David Einhorn Comments on Mylan - Jan 19, 2016

We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant.

We acknowledge eventual headwinds for the company’s branded EpiPen product, whichcould encounter competition from generics in late 2016. However, we see medium-termupside from a competitor recall, an announced share repurchase, and board review ofcorporate governance complaints. Ultimately, we expect MYL to earn close to $7 per share in2018, driven by a robust pipeline of respiratory, injectable and biologic drugs and by furthercapital deployment including share repurchases. We initiated our position at an average priceof $45.32, about 9x 2016 consensus EPS estimates. MYL shares ended the quarter at $54.07.

From David Einhorn (Trades, Portfolio)'s Green Light Capital fourth quarter 2015 shareholder letter.

Check out David Einhorn latest stock trades

Keeley Funds Comments on Mylan NV - Nov 03, 2015

The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative impact on the entire industry.





From the Keeley All-Cap Value Fund commentary on third quarter 2015.



Check out John Keeley latest stock trades

Top Ranked Articles about Mylan NV

Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Mylan to Report Second Quarter 2017 Financial Results on Aug. 9, 2017
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab
Steven Romick Buys Mylan, Adds to 4 Holdings in 2nd Quarter Investor discloses second-quarter portfolio
Returns for Steve Romick’s FPA Crescent Fund rose 4.38% year to date, compared to the S&P 500, which stretched 8.42%. Read more...
Adamis Pharmaceuticals’ EpiPen Alternative Approved Mylan faces competition from new product
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) announced June 15 its epinephrine injection had been approved by the U.S. Food and Drug Administration, giving EpiPen manufacturer Mylan NV (NASDAQ:MYL) a run for its money. Read more...
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions
The Fading Fortunes of John Paulson Hedge fund guru won attention for his strategy during the subprime crisis, but lately he’s been getting attention for the wrong reasons
John Paulson (Trades, Portfolio) was once a darling of Wall Street, having handsomely profited because of his smart bets on the subprime crisis while many of his counterparts suffered. Read more...
Mylan to Present at Goldman Sachs 38th Annual Global Healthcare Conference
Mylan Launches Generic Azilect® Tablets

Ratios

vs
industry
vs
history
PE Ratio 38.40
MYL's PE Ratio is ranked lower than
67% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.93 vs. MYL: 38.40 )
Ranked among companies with meaningful PE Ratio only.
MYL' s PE Ratio Range Over the Past 10 Years
Min: 7.32  Med: 26.41 Max: 112.56
Current: 38.4
7.32
112.56
Forward PE Ratio 7.53
MYL's Forward PE Ratio is ranked higher than
93% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. MYL: 7.53 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 38.40
MYL's PE Ratio without NRI is ranked lower than
66% of the 554 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.21 vs. MYL: 38.40 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.32  Med: 26.41 Max: 112.56
Current: 38.4
7.32
112.56
Price-to-Owner-Earnings 52.86
MYL's Price-to-Owner-Earnings is ranked lower than
67% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.90 vs. MYL: 52.86 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.37  Med: 34.63 Max: 310
Current: 52.86
13.37
310
PB Ratio 1.80
MYL's PB Ratio is ranked higher than
70% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. MYL: 1.80 )
Ranked among companies with meaningful PB Ratio only.
MYL' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.51 Max: 7.02
Current: 1.8
0.64
7.02
PS Ratio 1.78
MYL's PS Ratio is ranked higher than
67% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. MYL: 1.78 )
Ranked among companies with meaningful PS Ratio only.
MYL' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.76 Max: 3.94
Current: 1.78
0.4
3.94
Price-to-Free-Cash-Flow 12.14
MYL's Price-to-Free-Cash-Flow is ranked higher than
79% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. MYL: 12.14 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.82  Med: 19.89 Max: 115.12
Current: 12.14
8.82
115.12
Price-to-Operating-Cash-Flow 8.50
MYL's Price-to-Operating-Cash-Flow is ranked higher than
83% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. MYL: 8.50 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.07  Med: 11.83 Max: 40.9
Current: 8.5
6.07
40.9
EV-to-EBIT 50.38
MYL's EV-to-EBIT is ranked lower than
84% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. MYL: 50.38 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.3  Med: 19.3 Max: 74.5
Current: 50.38
-10.3
74.5
EV-to-EBITDA 15.02
MYL's EV-to-EBITDA is ranked higher than
57% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. MYL: 15.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.2 Max: 23.3
Current: 15.02
-17.7
23.3
PEG Ratio 9.14
MYL's PEG Ratio is ranked lower than
88% of the 313 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. MYL: 9.14 )
Ranked among companies with meaningful PEG Ratio only.
MYL' s PEG Ratio Range Over the Past 10 Years
Min: 0.72  Med: 2.78 Max: 13.61
Current: 9.14
0.72
13.61
Shiller PE Ratio 91.10
MYL's Shiller PE Ratio is ranked lower than
81% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. MYL: 91.10 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.48  Med: 83.75 Max: 173.66
Current: 91.1
14.48
173.66
Current Ratio 1.56
MYL's Current Ratio is ranked lower than
70% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MYL: 1.56 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 4.82 Max: 11.71
Current: 1.56
0.83
11.71
Quick Ratio 1.00
MYL's Quick Ratio is ranked lower than
76% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. MYL: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.53 Max: 8.47
Current: 1
0.55
8.47
Days Inventory 130.46
MYL's Days Inventory is ranked lower than
56% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. MYL: 130.46 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 133.92 Max: 168.24
Current: 130.46
88.95
168.24
Days Sales Outstanding 80.77
MYL's Days Sales Outstanding is ranked lower than
56% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. MYL: 80.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.49  Med: 86.72 Max: 107.26
Current: 80.77
77.49
107.26
Days Payable 40.65
MYL's Days Payable is ranked lower than
79% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. MYL: 40.65 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 40.65  Med: 70.84 Max: 101.21
Current: 40.65
40.65
101.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.90
MYL's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. MYL: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -1 Max: 7.4
Current: -12.9
-25.8
7.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.17
MYL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. MYL: 1.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.59 Max: 5.33
Current: 1.17
0.62
5.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.59
MYL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
90% of the 83 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. MYL: 3.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.01
MYL's Price-to-Median-PS-Value is ranked higher than
58% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. MYL: 1.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 2.2 Max: 8.12
Current: 1.01
0.37
8.12
Earnings Yield (Greenblatt) % 1.98
MYL's Earnings Yield (Greenblatt) % is ranked lower than
58% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYL: 1.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -27.5  Med: 4.8 Max: 19
Current: 1.98
-27.5
19
Forward Rate of Return (Yacktman) % 8.36
MYL's Forward Rate of Return (Yacktman) % is ranked lower than
53% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. MYL: 8.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 13.2 Max: 24.9
Current: 8.36
7.8
24.9

More Statistics

Revenue (TTM) (Mil) $11,605.10
EPS (TTM) $ 1.02
Beta1.47
Short Percentage of Float3.50%
52-Week Range $33.60 - 50.40
Shares Outstanding (Mil)535.98

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 12,478 12,986 13,596
EPS ($) 5.13 5.69 6.21
EPS without NRI ($) 5.13 5.69 6.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.83%
Dividends per Share ($)
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revef Jul 19 2017 
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revef Jul 19 2017 
Mylan to Report Second Quarter 2017 Financial Results on Aug. 9, 2017 Jul 19 2017 
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Propose Jul 13 2017 
Steven Romick in 2nd Quarter Buys Mylan, Adds to 4 Other Holdings Jul 10 2017 
Adamis Pharmaceuticals’ EpiPen Alternative Approved Jun 15 2017 
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77 Jun 10 2017 
The Fading Fortunes of John Paulson Jun 08 2017 
Mylan to Present at Goldman Sachs 38th Annual Global Healthcare Conference Jun 07 2017 
Mylan Launches Generic Azilect® Tablets Jun 02 2017 

More From Other Websites
Biotech Movers: Sarepta, Inovio, Mylan Jul 20 2017
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of... Jul 19 2017
Mylan NV breached its 50 day moving average in a Bearish Manner : MYL-US : July 19, 2017 Jul 19 2017
Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod Jul 17 2017
ETFs with exposure to Mylan NV : July 14, 2017 Jul 14 2017
Bank shares fall, AT&T says CEO stays CEO Jul 14 2017
What Allergan’s Valuation as of July 13 Tells Us Jul 14 2017
Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co. Jul 14 2017
Mylan's Breast Cancer Drug Wins FDA Advisors' Approval Jul 14 2017
After-hours buzz: CYBR, MYL & more Jul 13 2017
Mylan shares rise as FDA advisors recommend breast-cancer drug approval Jul 13 2017
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's... Jul 13 2017
Today's Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Mylan N.V. Jul 13 2017
Steven Romick Buys Mylan, Adds to 4 Holdings in 2nd Quarter Jul 10 2017
[$$] Maryland Sued by Generic-Drug Trade Group Over New Pricing Law Jul 07 2017
Pfizer receives token payment to exit Brazil venture, sources say Jul 04 2017
3 Surprising Reasons Drug Stocks Tank Every Time the Republican Health Bill Hits a Snag Jul 04 2017
EpiPen Maker Mylan Urged by Activist Funds to Remove Directors After Shareholder No Vote Is Revealed Jun 29 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}